Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Solid Biosciences (Nasdaq: SLDB), a company dedicated to therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a company dedicated to therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 am ET. A Q&A session will follow the presentation. Institutional investors can book meetings with management through their J.P. Morgan representatives. A live webcast will be available on the company’s Investors page, along with an archived replay for 30 days.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was -1.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET. Following the prepared remarks, Mr. Ganot will be available for Q&A.
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Caitlin Lowie
Solid Biosciences
607-423-3219
clowie@solidbio.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.